Ashish Kamat, MD presents on the myths and mysteries surrounding adjuvant therapy for non-muscle invasive bladder cancer (NMIBC). Dr. Kamat explains the non-homogenous characteristics and lack of uniformity in risk factors of NMIBC. He discusses study results of BCG contribution to reduction in progression of NMIBC when maintenance is used.